Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

被引：975

作者：

Pao, William ^{[1
]}

Chmielecki, Juliann ^{[2
]}

机构：

[1] Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN 37232 USA

[2] Weill Cornell Grad Sch Med Sci, New York, NY 10021 USA

来源：

NATURE REVIEWS CANCER | 2010年 / 10卷 / 11期

基金：

美国国家卫生研究院;

关键词：

GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITOR; PREVIOUSLY TREATED PATIENTS; PHASE-III TRIAL; GENE COPY NUMBER; NONSMALL-CELL; ACQUIRED-RESISTANCE; T790M MUTATION; BCR-ABL; INCREASED SENSITIVITY;

D O I：

10.1038/nrc2947

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The disease has been the subject of intensive research at both the basic scientific and clinical levels, becoming a paradigm for how to understand and treat oncogene-driven carcinomas. Although patients with EGFR-mutant tumours have increased sensitivity to tyrosine kinase inhibitors (TKIs), primary and acquired resistance to these agents remains a major clinical problem. This Review summarizes recent developments aimed at treating and ultimately curing the disease.

引用

页码：760 / 774

页数：15

共 180 条

[1]

Albanell J, 2002, J CLIN ONCOL, V20, P110, DOI 10.1200/JCO.20.1.110

[2]

Cl-1033, an irreversible pan-erbB receptor inhibitor and its potential atmlication for the treatment of breast cancer [J].

Allen, LF ;

Eiseman, IA ;

Fry, DW ;

Lenehan, PF .

SEMINARS IN ONCOLOGY, 2003, 30 (05) :65-78

[3]

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[4]

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation [J].

Antonescu, CR ;

Besmer, P ;

Guo, TH ;

Arkun, K ;

Hom, G ;

Koryotowski, B ;

Leversha, MA ;

Jeffrey, PD ;

Desantis, D ;

Singer, S ;

Brennan, MF ;

Maki, RG ;

DeMatteo, RP .

CLINICAL CANCER RESEARCH, 2005, 11 (11) :4182-4190

[5]

Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations [J].

Avizienyte, Egle ;

Ward, Richard A. ;

Garner, Andrew P. .

BIOCHEMICAL JOURNAL, 2008, 415 (02) :197-206

[6]

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].

Balak, Marissa N. ;

Gong, Yixuan ;

Riely, Gregory J. ;

Somwar, Romel ;

Li, Allan R. ;

Zakowski, Maureen F. ;

Chiang, Anne ;

Yang, Guangli ;

Ouerfelli, Ouathek ;

Kris, Mark G. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501

[7]

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions [J].

Barr, Sharon ;

Thomson, Stuart ;

Buck, Elizabeth ;

Russo, Suzanne ;

Petti, Filippo ;

Sujka-Kwok, Izabela ;

Eyzaguirre, Alexandra ;

Rosenfeld-Franklin, Maryland ;

Gibson, Neil W. ;

Miglarese, Mark ;

Epstein, David ;

Iwata, Kenneth K. ;

Haley, John D. .

CLINICAL & EXPERIMENTAL METASTASIS, 2008, 25 (06) :685-693

[8]

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[9]

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma [J].

Bean, James ;

Riely, Gregory J. ;

Balak, Marissa ;

Marks, Jenifer L. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2008, 14 (22) :7519-7525

[10]

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].

Bean, James ;

Brennan, Cameron ;

Shih, Jin-Yuan ;

Riely, Gregory ;

Viale, Agnes ;

Wang, Lu ;

Chitale, Dhananjay ;

Motoi, Noriko ;

Szoke, Janos ;

Broderick, Stephen ;

Balak, Marissa ;

Chang, Wen-Cheng ;

Yu, Chong-Jen ;

Gazdar, Adi ;

Pass, Harvey ;

Rusch, Valerie ;

Gerald, William ;

Huang, Shiu-Feng ;

Yang, Pan-Chyr ;

Miller, Vincent ;

Ladany, Marc ;

Yang, Chih-Hsin ;

Pao, William .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937

← 1 2 3 4 5 6 7 8 9 10 →